ScholarX: PARK, YEON HEE

Detailed Information

PARK, YEON HEE (박연희)

Medicine (Medicine)

Research Area

Tel 02-3410-1780
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast cancer:34||breast cancer:25||Breast neoplasms:23||Metastatic breast cancer:16||HER2:11||Prognosis:9||metastatic breast cancer:9||Neoadjuvant chemotherapy:9||Chemotherapy:9||Breast neoplasm:8||Overall survival:8||chemotherapy:7||Nonsmall cell lung cancer:7||triplenegative breast cancer:7||Triplenegative breast cancer:6||Paclitaxel:6||Immunohistochemistry:6||3:6||Eribulin:6||Quality of life:5||neoadjuvant chemotherapy:5||Mutation:5||Brain metastasis:5||Pathologic complete response:5||Progressionfree survival:4||HER2 positive:4||Neoplasm metastasis:4||Capecitabine:4||BRCA1:4||early breast cancer:4||Recurrence:4||Palbociclib:4||brain metastasis:4||trastuzumab deruxtecan:4||Advanced breast cancer:4||Trastuzumab:4||cisplatin:3||Clinical trial:3||residual cancer burden:3||PanAsian:3||Neoadjuvant therapy:3||Hormone receptor:3||ErbB2 receptor:3||Wholebrain radiotherapy:3||treatment:3||Young breast cancer:3||Metastasis:3||Lung cancer:3||realworld data:3||Gefitinib:3||prognosis:3||EGFR:3||HER2positive breast cancer:3||neoadjuvant therapy:3||HER2positive:3||Asian:3||advanced breast cancer:3||PDL1:3||Brain metastases:2||s lymphoma:2||HER2overexpressing breast cancer:2||staging:2||Stomach neoplasms:2||surveillance:2||survival:2||epidermal growth factor receptor:2||Survival:2||Cardiotoxicity:2||Palliative chemotherapy:2||Cellfree DNA:2||Luminal breast cancer:2||triple negative breast cancer:2||12:2||Circulating tumor cells:2||Female:2||Pemetrexed:2||Cisplatin:2||81:2||Pertuzumab:2||guidelines:2||<:2||92:2||Fulvestrant:2||Phosphatidylinositol 3kinases:2||Thymidylate synthase:2||Gemcitabine:2||immune checkpoint:2||immune checkpoint inhibitor:2||Treatment outcome:2||immunotherapy:2||Triple negative:2||Adjuvant chemotherapy:2||Human epidermal growth factor receptor 2:2||ESMO:2||Triplenegative breast neoplasms:2||Premenopausal:2||BRCA2:2||4:2||Biomarker:2||Tumorinfiltrating lymphocytes:2||Prognostic biomarker:2||Prognostic biomarkers:2||Prognostic factors:2||Endocrine therapy:2||Epidemiology:2||Neoadjuvant:2||Radiation therapy:2||nonsmall cell lung cancer:2||Radiotherapy:2||overall survival:2||Immunotherapy:2||Erlotinib:2||pathologic complete response:2||Asia:2||pembrolizumab:2||brain metastases:2||Neutropenia:2||breast neoplasm:2||poziotinib:2||cMET:2||Nextgeneration sequencing:2||Nomogram:2||capecitabine:2||capivasertib:2||Irinotecan:2||prognostic factor:2||circulating tumor DNA:2||CDK4:2||clinical trials:2||radiotherapy:2||Ki67:2||Korean:2||CDK4/6 inhibitor:2||Docetaxel:2||HER2+breast cancer:2||5:2||Oxaliplatin:2||236:2||HER2 expression:1||HER2 mutation:1||HER2 positivity:1||HER2+:1||HER2+metastatic breast cancer:1||HER2advanced breast cancer:1||HER2low:1||HER2low breast cancer:1||HER2targeted therapy:1||HER3:1||HR + /HER2:1||HR plus:1||HR+/HER2− breast cancer:1||HRlow/HER2breast cancer:1||Hair density:1||Hair thickness:1||Head and neck:1||Head and neck cancer:1||Hepatobiliary disorder:1||Her2:1||Homologous recombination repair deficiengy (HRD):1||Hormonal receptor:1||Hormone receptor positive:1||Hormone receptorpositive breast cancer:1||Hormone receptors:1||Human epidermal growth factor receptor 2 (HER2):1||Hydrating nail solution:1||Hyperglycemia:1||IFNγ:1||IGF1R:1||IGFBP3:1||IMC001:1||Immune checkpoint inhibitors:1||Immune gene signature:1||Immune subtypes:1||Immunerelated adverse events:1||Immunity:1||Incidence:1||Interstitial lung disease:1||Intratumoral heterogeneity:1||Intrinsic molecular subtype:1||Intrinsic subtype:1||KaplanMeier survival curves:1||Korea:1||Korean ethnicity:1||Koreans:1||LAG3:1||LargeB cell:1||Left ventricular ejection fraction:1||Leptomeningeal metastases:1||Leptomeningeal metastasis:1||Local neoplasm recurrence:1||Local recurrence:1||Locoregional recurrence:1||Locoregional therapy:1||Long survival outcomes:1||Longacting granulocytecolony stimulating factor:1||Lymph node:1||Lymph node excision:1||Lymph node ratio:1||Lymph nodes:1||Lymphatic irradiations:1||Lymphoma:1||Lymphovascular invasion:1||METABRIC:1||MMP1:1||MRI:1||Machine learning:1||Magnetic resonance imaging (MRI):1||Maintenance therapy:1||Matrix metalloproteinase:1||Metastatic breast cancer (MBC):1||MitoRAISE:1||Mitochondrial function:1||Molecular subtypes:1||Molecular targeted therapy:1||Mucin 1 expressi:1||Mucosal melanoma:1||Multimodality:1||N3:1||NATALEE:1||NEPA:1||NFkappa B:1||NSCLC:1||Nausea and vomiting:1||Neoadjuvant TCHP regimen:1||Neoplasm:1||Nerve growth factor:1||Neuroendocrine tumor:1||Neuropathy:1||Neversmokers:1||Nivolumab:1||Obesity:1||Objective measured:1||Olaparib:1||Oligometastases:1||Oncology:1||Onycholysis:1||Outcomes:1||Ovarian protection:1||Ovarian suppression:1||PAM50:1||PAR framework:1||PARP inhibitors:1||PD1:1||PET CT:1||PIK3CA:1||PTEN:1||Palliative:1||Patient reported outcome:1||Patient selection:1||Patientreported outcome (PRO):1||Pattern of care study:1||Pegylated GCSF:1||Pem:1||Pembrolizumab:1||Peritoneum:1||Permanent chemotherapyinduced alopecia:1||Pharmacovigilance:1||Phase I study:1||Phase II trial:1||Phase IV clinical trial:1||Pleomorphic carcinoma:1||Population characteristics:1||Postmarketing surveillance:1||Postmenopause:1||Practice guideline:1||Precision medicine:1||Precision oncology:1||Prediction model:1||Predictive factor:1||Predictors:1||Premenopausal breast cancer:1||Primary systemic therapy:1||Prior chemotherapy:1||Progesterone receptors:1||Prognostic diagnosis:1||Prognostic factor:1||Prognostic model:1||Proportion:1||Prospective cohort study:1||Pulmonary embolism:1||Pulmonary pleomorphic carcinoma:1||Pure mucinous adenocarcinoma:1||RANKL:1||Race:1||Randomized phase II trial:1||Real world evidence:1||RealWorld Data:1||Realworld data:1||Receptor:1||Recursive partitioning analysis:1||Regional:1||Relapse pattern:1||Relapsefree survival:1||Relative mitochondrial ATP synthesis rate:1||Response:1||Response criteria:1||Retrospective Analysis:1||Risk:1||S1:1||SGLT2 inhibitor:1||Safety:1||Salvage therapy:1||Salvage treatment:1||Segmental mastectomy:1||Skeletalrelated event:1||Skin changes:1||Smoking status:1||Social determinants of health:1||Social support:1||Socioeconomic status:1||Soft tissue infiltration:1||Solid tumor:1||Somatic mutations:1||Spinal cord compression:1||Squamous cell carcinoma:1||Squamous cell carcinoma of the head and neck:1||Subtype:1||Survival Outcome:1||Survival outcomes:1||Systemic therapy:1||TDM1:1||TDXd:1||Tcell nonHodgkin&apos:1||Tlymphoblastic lymphoma:1||TAC chemotherapy:1||TCGA:1||TCHP:1||TGFα:1||TGFβ1:1||TNFα:1||TNM stage:1||TNM staging:1||TP53:1||Tamoxifen:1||Targeted therapy:1||Therapeutics:1||Thymidine phosphorylase:1||Topical lotion:1||Transcriptomics:1||Trastuzumab biosimilar:1||Trastuzumab deruxtecan:1||Trastuzumab emtansine:1||Treatment:1||Triple negative breast cancer:1||Triple negative breast cancer (TNBC):1||Triple negative breast neoplasms:1||Triplenegative Breast Neoplasms:1||Tumor marker:1||Tumor microenvironment:1||Tumor molecular subtype:1||Tumor mutational burden (TMB):1||Tumor suppressor protein p53:1||Unfavorable:1||Unknown primary:1||VP shunt:1||Vinorelbine:1||Visceral:1||White ethnicity:1||Whole brain radiotherapy:1||adenocarcinoma:1||adenovirus:1||adjuvant cohort:1||adjuvant therapy:1||adotrastuzumab emtansine:1||altered appearance distress:1||amphiregulin:1||antibodydrug conjugate:1||antibodydrug conjugates:1||antibody–drug conjugates:1||antiemetics:1||atezolizumab:1||biomarker:1||biomarkers:1||bisphosphonate:1||body
image:1||bone marrow:1||brain metastas:1||breast:1||ckit:1||cmet:1||camizestrant:1||cancer drug:1||cancer immunotherapy:1||cardiovascular event:1||clinical data warehouse:1||computational biology:1||consensus:1||consultation and referral:1||critical presentations:1||ctDNA:1||cyclindependent kinase 4 and 6 inhibitors:1||cytology:1||data collection:1||datopotamab deruxtecan:1||diagnostic value:1||diarrhea:1||diffuse large Bcell lymphoma:1||disease free survival:1||diseasefree interval:1||drug development:1||durvalumab:1||ejection fraction:1||endocrine symptoms:1||endocrine therapy:1||endocrine therapy resistance:1||erlotinib:1||eventfree survival:1||excesion repair crosscomplementation group 1 (ERCC1):1||exosomes:1||expression assay:1||extracellular vesicles:1||extracranial disease control:1||fertility preservation:1||first line:1||fluorodeoxyglucosepositron emission tomography:1||fulvestrant:1||gastric cancer:1||gastric lymphoma:1||gefitinib:1||gemcitabine:1||gene:1||genetic polymorphism:1||hepatitis B virus:1||highgrade lymphoma:1||highgrade serous carcinoma:1||hormonal therapy:1||hormone receptor:1||hormone receptor positive:1||hormone receptor positive (HR+):1||hormone receptorpositive:1||hormonereceptorpositive breast cancer:1||human:1||human epidermal growth factor receptor 2negative:1||hyperglycemia:1||immune signature:1||incadronate:1||interleukin10:1||intestinal:1||intracranial:1||irinotecan:1||isolated locoregional recurrence:1||kras:1||longdelayed CINV:1||lung:1||lymphoma:1||machine learning:1||malignancyassociated hypercalcemia:1||marginal zone B cell lymphoma:1||marginal zone Bcell lymphoma:1||marginal zone Bcell lymphoma of MALT type:1||mechanism:1||medical record:1||metastatic:1||metastatic breast cancer (MBC):1||metastatic breast carcinoma:1||molecular subtype:1||molecular subtypes:1||mtDNA copy number:1||mutation:1||nCounter mRNA expression assay:1||neoadjuvant chemotherapy:1||neoadjuvant:1||neoadjvant chemotherapy:1||netupitant and palonosetron:1||next generation sequencing (NGS):1||nonHodgkin lymphoma:1||nonHodgkin&apos:1||nongastric:1||observational study:1||oesophageal cancer:1||p53:1||palbociclib:1||palbociclib with letrozole:1||patientreported outcome:1||patientreported outcome measures:1||pertuzumab:1||pharmacogenetics:1||phosphorylated signal transducer and activator of transcription 3:1||platinum chemotherapy:1||pooled analysis:1||positron emission tomography:1||prediction model:1||predictor:1||pregnancy:1||preliminary attainability assessment:1||premenopausal:1||premenopause:1||prevalence:1||primary resistance:1||progesterone receptor:1||prognostic biomarker:1||prognostic index:1||programmed death ligand 1:1||prospective cohort:1||radiation therapy:1||rapid relapse:1||rash:1||real time prediction:1||recurrence:1||recurrence model:1||refractory:1||refractory metastatic breast cancer:1||relevance:1||reliability:1||residual proliferative cancer burden:1||ribociclib:1||routine followup:1||safety:1||salvage chemotherapy:1||second line treatment:1||selective estrogen receptor degrader:1||single nucleotide polymorphism:1||socioeconomic status:1||spatial analysis:1||surgery:1||survivorship:1||targeted deep sequencing:1||targeted sequencing:1||taxane:1||thymidine phosphorylase (TP):1||thymidine synthase (TS):1||traffic exposure:1||trastuzumab:1||trastuzumab emtansine:1||tumor:1||tumor response:1||tyrosine kinase inhibitors:1||vaccine:1||vascular endothelial growth factor A:1||vascular endothelial growth factor receptor 1:1||whole exome sequencing (WES):1||wild type:1||women's health:1||young:1||young age:1||1:1||2:1||26143675592760:1||2614922769:1||2614923532237076502700:1||26149235322373:1||283217:1||312:1||3282330646143760:1||328246447627374510025:1||6 inhibitor:1||6 inhibitors:1||= 1 cm Invasive breast cancer:1||= 1 cm i:1||A proliferationinducing ligand:1||AJCC 8th edition:1||APOBEC3B germline deletion:1||ATP:1||Adjuvant Treatment:1||Adjuvant radiotherapy:1||Adjuvant treatment:1||Advanced nonsmall cell lung cancer:1||Aged:1||Alopecia:1||Alpelisib:1||AmpliSeq:1||Anthracycline and taxanepretreated:1||AntiHER2 targeted therapy:1||Anticoagulation:1||Asians:1||Asymptomatic brain metastases in NSCLC:1||Axillary lymph node:1||Bcell lymphoma:1||BRCA 1/2:1||BRCA mutation:1||BRCA mutations:1||BcrAbl:1||Biology:1||Biomarkers:1||Body mass index:1||Bone:1||Botanical:1||Brain:1||Braindirected treatment:1||Breast:1||Breast Neoplasms:1||Breast cancer 1 gene product:1||Breast cancer 2 gene product:1||Breast cancer subtype:1||Breast cancer subtypes:1||Breast carcinoma:1||Breast conserving:1||CXC motif chemokine ligand 13:1||CA 153:1||CD40L:1||CDW:1||CSIHC4:1||California Cancer Registry:1||Capecitabine monotherapy:1||Chemotherapyinduced skin change:1||Classification:1||Clinical outcome:1||Clinical outcomes:1||Cohort:1||Cohort profile:1||Combined endocrine therapy:1||Combined modality therapy:1||Comparison:1||Consensus:1||Costs and cost analysis:1||DESTINYBreast01:1||DNA sequencing:1||DS8201:1||Dermatomyositis:1||Diffuse:1||Disparities:1||Double primary tumor:1||Drug eruptions:1||Drug resistance:1||Drug therapy:1||Dryness:1||Dullness:1||Dura mater:1||Durable responders:1||Durable response:1||Dyslipidemia:1||E7:1||EGF:1||ER:1||ER status:1||ERhigh:1||ERlow:1||ERBB2 neutral:1||ESMO guidelines:1||ESR1 mutation:1||Early failure:1||East Asia:1||Employment:1||ErbB2:1||Esophageal cancer:1||Esophageal neoplasms:1||Esophageal squamous cell carcinoma:1||Esophagorespiratory fistula:1||Estrogen receptor:1||Estrogen receptorpositive:1||Estrogen receptors:1||Ethnic diversity:1||Ethnicity:1||Ets1:1||Exosomes:1||Extracellular vesicles:1||FDA Adverse Event Reporting System:1||FDG PET:1||FGFR:1||Family history:1||Firstline:1||Firstline palliative chemotherapy:1||Founder variant:1||Founders:1||Fracture:1||Functional assessment of cancer therapytaxane questionnaires:1||Gene expression profiling:1||Gene signature:1||Genes:1||Genetic:1||Genetic alteration:1||Genetic counseling:1||Genomic alterations:1||Genomic profile:1||Genomics:1||Giredestrant:1||Gonadotropinreleasing hormone agonist:1||Guideline:1||HER pathway:1||HER2:1||HER2 negative:1||HER2negative metastatic breast cancer:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE